AprilBio announces paid-in capital increase
에이프릴바이오
397030
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2719
Risk-adjusted indicator based on 2719 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Initial Conversion Price: 42,953 KRW per share
- • Minimum Preferred Dividend Rate: 1% of par value per share annually
- • Conversion Price Adjustment Floor: 70% of initial conversion price
AI Analysis Summary
AprilBio Co.,Ltd. has announced a decision on a paid-in capital increase. The new shares will be preferred shares with an initial conversion price of 42,953 KRW per share. These preferred shares offer a minimum annual dividend of 1% of their par value and are cumulative and participating. The conversion price can be adjusted downwards, but not below 70% of the initial conversion price. This capital increase could lead to dilution for existing common shareholders upon conversion of the preferred shares. The purpose of the funds and the number of shares to be issued are not specified in the provided content, limiting a full assessment of the dilution impact.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.